CoreRx™ Celebrates Its First Year of Operations

Tampa, FL, August 03, 2007 --(PR.com)-- CoreRx™ celebrates its first year of operations 01 August2007. In their initial year of business CoreRx™ has serviced more than 25 clients, both domestic and abroad. The company has positioned themselves for successful growth strategies over the next few years. Included in CoreRx’s™ growth strategy is the collaborative agreement between CoreRx™ and JRS Pharma, one of the world's leading excipient manufacturers, to stabilize drug molecules using JRS’ patented PROSOLV® technology. Also, included in CoreRx’s™ growth strategy, is the company's strict dedication to continually increase capital expenditures for equipment procurement in order to keep current and future clients on track for their respective goals and timelines. A number of clients have already returned to CoreRx™ for repeat business. One of the company's largest clients stated, "The services provided are at a very reasonable price, coupled with superior client communication and efficient turn-around times without sacrificing the integrity or quality of work."

CoreRx™ focuses on supporting and streamlining the drug development process for biotechnology and pharmaceutical innovators by offering services such as pre-formulation/formulation development, analytical development, clinical manufacturing and validation engineering. They have a proven track record and extensive expertise providing comprehensive drug development services to biotechnology and pharmaceutical companies worldwide.

“Our primary goal at CoreRx™ is to maintain open communications with our clients, so that we can provide innovative solutions on budget while maintaining our core values of quality, integrity, and efficiency”.

The facility is conveniently located in Tampa, Florida, a few miles from the Tampa International Airport. For more information, visit their website at www.corerxpharma.com or call (813) 514-9399.

###